Literature DB >> 19996069

Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction.

Scott D Solomon1, Anil Verma, Akshay Desai, Amira Hassanein, Joseph Izzo, Suzanne Oparil, Yves Lacourciere, Joleen Lee, Yodit Seifu, Robert J Hilkert, Ricardo Rocha, Bertram Pitt.   

Abstract

Diastolic dysfunction may precede development of heart failure in hypertensive patients. We randomized 228 patients with uncontrolled hypertension, preserved ejection fraction, and diastolic dysfunction to 2 targeted treatment strategies: intensive, with a systolic blood pressure target of <130 mm Hg, or standard, with a systolic blood pressure target of <140 mm Hg, using a combination of valsartan, either 160 or 320 mg, plus amlodipine, either 5 or 10 mg, with other antihypertensive medications as needed. Echocardiographic assessment of diastolic function was performed at baseline and after 24 weeks in a prospective, open-label, blinded end point design. Blood pressure was reduced significantly in both groups, from 161.2+/-13.9/90.1+/-12.0 to 130.8+/-12.3/74.9+/-9.1 mm Hg (P<0.0001) in the intensive arm and from 162.1+/-13.2/93.7+/-12.2 to 137.0+/-12.9/79.6+/-11.0 mm Hg (P<0.0001) in the standard arm (P<0.003 for between-group comparisons). Myocardial relaxation velocity improved from 7.6+/-1.1 to 9.2+/-1.7 cm/s (Delta 1.54+/-1.4 cm/s; P<0.0001) in the intensive arm and from 7.5+/-1.3 to 9.0+/-1.9 cm/s (Delta 1.48+/-1.6 cm/s; P<0.0001) in the standard arm, with no difference between the 2 strategies in the achieved improvement (P=0.58). The degree of improvement in annular relaxation velocity was associated with the extent of systolic blood pressure reduction, and patients with the lowest achieved systolic blood pressure had the highest final diastolic relaxation velocities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19996069     DOI: 10.1161/HYPERTENSIONAHA.109.138529

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  36 in total

Review 1.  Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions.

Authors:  Bharathi Upadhya; Dalane W Kitzman
Journal:  Am J Cardiovasc Drugs       Date:  2017-08       Impact factor: 3.571

2.  Differential effects of late-life initiation of low-dose enalapril and losartan on diastolic function in senescent Fischer 344 x Brown Norway male rats.

Authors:  Leanne Groban; Sarah Lindsey; Hao Wang; Marina S Lin; Kimberly A Kassik; Frederico S M Machado; Christy S Carter
Journal:  Age (Dordr)       Date:  2011-07-01

Review 3.  Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.

Authors:  Pedro Marques da Silva
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 4.  Alterations in cardiac structure and function in hypertension.

Authors:  Mário Santos; Amil M Shah
Journal:  Curr Hypertens Rep       Date:  2014-05       Impact factor: 5.369

Review 5.  Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update.

Authors:  Alberto Milan; Mimma A Caserta; Eleonora Avenatti; Sara Abram; Franco Veglio
Journal:  Intern Emerg Med       Date:  2010-05-18       Impact factor: 3.397

Review 6.  Heart failure with preserved ejection fraction in the elderly: scope of the problem.

Authors:  Bharathi Upadhya; George E Taffet; Che Ping Cheng; Dalane W Kitzman
Journal:  J Mol Cell Cardiol       Date:  2015-03-06       Impact factor: 5.000

7.  Mast Cell Inhibition Attenuates Cardiac Remodeling and Diastolic Dysfunction in Middle-aged, Ovariectomized Fischer 344 × Brown Norway Rats.

Authors:  Hao Wang; Jaqueline da Silva; Allan Alencar; Gisele Zapata-Sudo; Marina R Lin; Xuming Sun; Sarfaraz Ahmad; Carlos M Ferrario; Leanne Groban
Journal:  J Cardiovasc Pharmacol       Date:  2016-07       Impact factor: 3.105

8.  Cardiovascular responses to rhythmic handgrip exercise in heart failure with preserved ejection fraction.

Authors:  Stephen M Ratchford; Heather L Clifton; D Taylor La Salle; Ryan M Broxterman; Joshua F Lee; John J Ryan; Paul N Hopkins; Josephine B Wright; Joel D Trinity; Russell S Richardson; D Walter Wray
Journal:  J Appl Physiol (1985)       Date:  2020-09-17

9.  Attenuation of salt-induced cardiac remodeling and diastolic dysfunction by the GPER agonist G-1 in female mRen2.Lewis rats.

Authors:  Jewell A Jessup; Sarah H Lindsey; Hao Wang; Mark C Chappell; Leanne Groban
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

Review 10.  Therapeutic interventions for heart failure with preserved ejection fraction: A summary of current evidence.

Authors:  Muhammad Asrar ul Haq; Chiew Wong; Vivek Mutha; Nagesh Anavekar; Kwang Lim; Peter Barlis; David L Hare
Journal:  World J Cardiol       Date:  2014-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.